Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery

Current Chemical Genomics and Translational Medicine

Volumn 8, Issue , 2014, Pages 27-35

  Reid, Brian G ^a   Jerjian, Taleen ^a   Patel, Purvi ^a   Zhou, Qiong ^a   Yoo, Byong Hoon ^a   Kabos, Peter ^b   Sartorius, Carol A ^a   LaBarbera, Daniel V ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

And Cancer Drug Discovery; Cancer Stem Cells (CSC); Cytokeratin 5; High Content Screening (HCS); High Throughput Screening (HTS); Luminal Breast Cancer; Multicellular Tumor Spheroid (MCTS); Systems Biology

Indexed keywords

CYTOKERATIN 5; FLUOROURACIL; GREEN FLUORESCENT PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG SCREENING; FEMALE; FLUORESCENCE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SPHEROID;

EID: 84989237488     PISSN: None     EISSN: 22139885     Source Type: Journal    
DOI: 10.2174/2213988501408010027     Document Type: Article

References (42)

1. Sutherland RM, Inch WR, McCredie JA, Kruuv J. A multicomponent radiation survival curve using an in vitro tumour model. Int J Radiat Biol Relat Stud Phys Chem Med 1970; 18: 491-5.
2. Sutherland RM, McCredie JA, Inch WR. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst 1971; 46: 113-20.
3. Durand RE, Sutherland RM. Dependence of the radiation response of an in vitro tumor model on cell cycle effects. Cancer Res 1973; 33: 213-9.
4. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997; 57: 2388-93.
5. LaBarbera DV, Reid BG, Yoo BH. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Dis 2012; 0: 1-12.
6. Li Q, Chen C, Kapadia A, et al. 3D Models of epithelialmesenchymal transition in breast cancer metastasis: highthroughput screening assay development, validation, and pilot screen. J Biomol Screen 2011; 16: 141-54.
7. Olive PL, Durand RE. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metast Rev 1994; 13: 121-38.
8. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988; 240: 177-84.
9. West GW, Weichselbaum R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3665-8.
10. Santini MT, Rainaldi G. Three-dimensional spheroid model in tumor biology. Pathobiology 1999; 67: 148-57.
11. Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 2002; 111: 923-5.
12. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007; 8: 839-45.
13. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002; 70: 537-46.
14. Xu R, Boudreau A, Bissell MJ. Tissue architecture and function: dynamic reciprocity via extra-and intra-cellular matrices. Cancer Metast Rev 2009; 28: 167-76.
15. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006; 22: 287-309.
16. Zahir N, Weaver VM. Death in the third dimension: apoptosis regulation and tissue architecture. Curr Opin Genet Dev 2004; 14: 71-80.
17. Ghosh S, Spagnoli GC, Martin I, et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005; 204: 522-31.
18. Spencer VA, Xu R, Bissell MJ. Gene expression in the third dimension: the ECM-nucleus connection. J Mammary Gland Biol 2010; 15: 65-71.
19. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148: 3-15.
20. Robertson FM, Ogasawara MA, Ye Z, et al. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen 2010; 15: 820-9.
21. Rowehl RA, Crawford H, Dufour A, Ju J, Botchkina GI. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics Proteomics 2008; 5: 301-10.
22. Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-4.
23. Kreeger PK, Lauffenburger DA. Cancer systems biology: a network modeling perspective. Carcinogenesis 2010; 31: 2-8.
24. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroidbased drug screen: considerations and practical approach. Nat Protoc 2009; 4: 309-24.
25. Hsiao AY, Tung YC, Qu X, Patel LR, Pienta KJ, Takayama S. 384 hanging drop arrays give excellent Z-factors and allow versatile formation of co-culture spheroids. Biotechnol Bioeng 2012; 109: 1293-304.
26. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004; 9: 273-85.
27. le Roux L, Volgin A, Maxwell D, Ishihara K, Gelovani J, Schellingerhout D. Optimizing imaging of three-dimensional multicellular tumor spheroids with fluorescent reporter proteins using confocal microscopy. Mol Imaging 2008; 7: 214-21.
28. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011; 136:473-8.
29. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-13.
30. Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002; 82: 737-46.
31. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203: 661-71.
32. Cheang MC, Voduc D, Bajdik C, Leung S, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.
33. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-71.
34. Axlund SD, Yoo BH, Rosen RB, et al. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Canc 2013; 4: 36-49.
35. Kabos P, Haughian JM, Wang X, et al. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Tr 2011; 128: 45-55.
36. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 2008; 105: 5774-9.
37. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008; 93: 3295-8.
38. Yoo BH, Axlund SD, Kabos P, et al. A High-Content Assay to Identify Small-Molecule Modulators of a Cancer Stem Cell Population in Luminal Breast Cancer. J Biomol Screen 2012.
39. Zhang JH. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999; 4: 67-73.
40. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
41. Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review. Cancer Treat Rev 2002; 28: 165-80.
42. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-18.